GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit, also known as SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit, is faster, easier, more scalable and automatable alternative to the traditional neutralizing antibody tests, such as virus neutralization test (VNT), pseudo-virus neutralization test (pVNT) and plaque reduction neutralization test (PRNT). The kit has the capability of measuring functional neutralizing antibodies (NAbs) within an hour instead of the days required by the traditional tests. cPass Neutralization Antibody detection kit does not require live biological materials or strict biosafety containment for testing (i.e. BSL3 containment). GenScript has acquired CE mark (Europe), US FDA Emergency Use Authorization, HSA provisional approval (Singapore) and ANVISA authorization (Brazil).